Huntington's Disease
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - A capacitated individual, aged >= 18 years. - Genetically confirmed CAG-repeat expansion of >= 36 in the Huntingtin gene. - Either about to start with prescribed medication related to HD or already using one or more HD related drugs. HD-related drugs are drugs considered to treat symptoms that either are related to manifest HD or are prescribed in pre-motor manifest or prodromal HD stage for symptoms that may be attributed to HD. - Sufficient knowledge of the Dutch language to understand the subject information letter and sign the IC.
Exclusion criteria
Exclusion criteria: Any medical condition, in the view of the investigator, which might endanger subject*s safety and/or satisfactory participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage definite prescription changes in HD gene carriers with a divergent PGx CYP2C19 or CYP2D6 phenotype (poor and ultra-rapid metabolizers) versus those with a PGx phenotype in more normal range (extensive and intermediate metabolizers). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters/endpoints: - Overview of medication use by HD gene carriers in one year. - Accuracy of a one-year medication diary compared to pharmacy medication history surveys. Exploratory study parameters/endpoints - Identify potentially new genetic polymorphisms with pharmacogenetic action in HD gene carriers. | — |
Countries
Netherlands
Outcome results
None listed